http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Corbus Presents First Pre-Clinical Data for CRB-913 at the European Association for the Study of Diabetes 2022 Annual Conference
-
Corbus Pharmaceuticals to Present Virtually at the H.C. Wainwright 24th Annual Global Investment Conference
-
Corbus Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
Corbus Presents Latest Preclinical Data for CRB-601 at the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference
-
Corbus Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
-
Corbus Presents First Preclinical Data for CRB-601 at the American Association for Cancer Research (AACR) Annual Meeting
-
Corbus Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference
-
Corbus Pharma (CRBP) Reports Q4; Provides Corporate Updates
-
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Updates
-
JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th
-
Corbus Pharma (CRBP) Appoints Rachael Brake as Chief Scientific Officer
-
Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer
-
Corbus Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
-
Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference
-
Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
-
Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
-
Corbus Pharma (CRBP) Phase 3 Study of Lenabasum for Treatment of Dermatomyositis Did Not Meet Primary Endpoint
-
Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
-
Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
-
Corbus Pharma (CRBP) Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases
-
Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases
-
Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases
-
Corbus Pharma (CRBP) Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress
-
Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress
-
Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress
-
CORBUS PHARMACEUTICALS ANNOUNCES ADJOURNMENT OF ANNUAL MEETING
-
CORBUS PHARMACEUTICALS ANNOUNCES ADJOURNMENT OF ANNUAL MEETING
-
Corbus Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Updates
-
Corbus Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Updates
-
Corbus Pharmaceuticals to Present at Three Upcoming Investor Conferences
-
Corbus Pharmaceuticals to Present at Three Upcoming Investor Conferences
-
Corbus Pharma (CRBP) Reports Complete Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus
-
Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE)
-
Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE)
-
Corbus Pharma (CRBP) Announces Last Subject Visit in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
-
Corbus Pharmaceuticals Reports Last Subject Visit in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
-
Corbus Pharmaceuticals Reports Last Subject Visit in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
-
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results
-
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results
-
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
-
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
-
Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2020 Results on March 15, 2021
-
Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2020 Results on March 15, 2021
-
Corbus Pharmaceuticals Announces Presentations at the New York Academy of Sciences Webinar on Targeting the Endocannabinoid System to Treat Human Diseases
-
Corbus Pharmaceuticals Announces Presentations at the New York Academy of Sciences Webinar on Targeting the Endocannabinoid System to Treat Human Diseases
-
Corbus Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
-
Corbus Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
-
Corbus Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Updates
-
Corbus Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Updates
-
Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis
